Elimination : Only 3-22% is excreted unchanged in the urine (~30% of clearance occurs in the kidneys)
Wegovy Tablets: Initial dose (days 1 through 30): 1.5 mg orally once a day Dose escalation: Days 31 through 60: 4 mg orally once a day Days 61 through 90: 9 mg orally once a day SUBCUTANEOUS: Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose for glycemic control: 0.5 to 2 mg subcutaneously once a week, based on glycemic control If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose: Increase to 1 mg subcutaneously once a week
What is Peptide BPC-157 BPC-157 stands for Body Protection Compound 157, and it is a synthetic peptide derived from a protein found in the stomach
For peptides that will be used over time, bacteriostatic water is essential
Concurrent medications can affect tirzepatide pharmacodynamics
However, it is important to note that peptides administered subcutaneously may undergo local catabolism in the SubQ compartment before reaching systemic circulation, which can impact their bioavailability and therapeutic efficacy
